Daneng Li (@DanengLi) ranks #10 among US gi cancer KOLs on X in 2026, by engagement from fellow physicians. 14 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: BREAKWATER, KEYNOTE-937, ABC-HCC. CMS Open Payments lists $37,172 in 2025 general payments.
At a Glance
- 3 posts naming a trial in 2026
- 3 trials discussed by name
- GI Cancer: US #10 · 14 physicians engaged
- Leading physician voice: #2 of 12 physicians on KEYNOTE-937
- CMS Open Payments lists $37,172 in 2025 general payments.
This Month
What Daneng Li has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Who Amplifies Daneng Li
Physicians who reposted Daneng Li’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| GI Cancer | #10 | — | 14 | 22 | Full ranking |
Trials Daneng Li Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| BREAKWATER | 1 | #12 of 22 | Jan 10, 2026 |
| KEYNOTE-937 | 1 | #2 of 12 | Jan 9, 2026 |
| ABC-HCC | 1 | #4 of 7 | Jan 9, 2026 |
Daneng Li on BREAKWATER
Impressive follow up results from Breakwater showing promising OS trend with combination therapy for an aggressive CRC population. How to further improve giving already at quadruple therapy combination. Novel mechanisms of action needed for the future. @ASCO #GI26 https://t.co/Jqb7kFAczk
Daneng Li on KEYNOTE-937
keynote 937 negative study for adjuvant #HCC in line with prior results from IMbrave 050. Unfortunately, still lack of positive #HCC trials. Novel strategies needed since given uniqueness of HCC adjuvant population and underlying cirrhosis. #GI26 @ASCO https://t.co/JuRHotfCwd
Daneng Li on ABC-HCC
ABC-HCC in intermediate #HCC showing early time to treatment failure benefit with atezo bev versus TACE. If OS can be shown to be positive, a change of strategy from upfront liver directed therapy to saving it at progression to systemic therapy may be preferred. #GI26 @ASCO https://t.co/zbNS1jmeYJ
Daneng Li’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Great discussion by Dr. Daniel Lin. For Herizon study, agree with outdated comparator arm is big limitation so big question now is who would actually use it if our current SOC is not truly represented. @ASCO #GI26 https://t.co/WLZ4hrjClL
Agree with @jgong15. Good to see studies and investigators doing the right thing and reevaluating continuation of studies when new data becomes available and standards of care changes. Putting patients first is key. @ASCO #GI26 https://t.co/LYoWqqsKrR
Industry Payments
CMS Open Payments · 2025 general payments
$37,172 across 32 payments